What Does Selank Feel Like? Anxiolytic Peptide Experiences

Research Disclaimer: This article is for educational and informational purposes only. All peptides discussed are for laboratory and research use only. Not for human consumption. Always consult a qualified healthcare professional.

By the NorthPeptide Research Team

What Is Selank?

Selank (TKPRPGP) is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is based on tuftsin — a naturally occurring tetrapeptide with immunomodulatory properties — with a Pro-Gly-Pro tripeptide extension added to improve metabolic stability.

Selank has been approved as a pharmaceutical drug in Russia and Ukraine for the treatment of generalized anxiety disorder and asthenic conditions. It is administered intranasally in the clinical setting. In the research context, it is studied as an anxiolytic, nootropic, and immunomodulatory compound.

What Makes Selank Different from Benzodiazepines?

Benzodiazepines (diazepam, alprazolam, lorazepam) work by allosterically modulating GABA-A receptors — increasing the frequency of chloride channel opening in response to GABA binding. They are highly effective anxiolytics but carry significant downsides: sedation, cognitive impairment, dependence, tolerance, and withdrawal.

Selank also interacts with the GABAergic system, but the mechanism appears to be different — more modulatory than directly agonistic. Research suggests Selank influences GABA metabolism and receptor sensitivity rather than directly activating the chloride channel in the manner benzodiazepines do. Animal studies have shown anxiolytic effects comparable to diazepam in certain models, but without the sedation and motor impairment associated with benzodiazepines.

Additionally, Selank affects multiple other systems — serotonin, dopamine, BDNF — giving it a broader neuromodulatory profile that may explain why it does not produce the cognitive blunting typical of benzodiazepines.

What Does the Research Say About Selank’s Activity Profile?

Published research on Selank documents the following:

• Anxiolytic effects: Multiple animal model studies demonstrating reduced anxiety behavior in elevated plus maze and open field tests
• BDNF upregulation: Selank has been shown to increase BDNF (brain-derived neurotrophic factor) expression — relevant to neuroprotection and neuroplasticity
• Serotonin system effects: Studies show Selank influences serotonin metabolism and receptor expression in relevant brain regions
• Immune modulation: As a tuftsin derivative, Selank retains immunomodulatory properties — clinical research in anxious patients showed effects on IL-6, interferon gamma, and IL-10
• Cognitive enhancement: Improved learning and memory in rodent models, attributed partly to BDNF upregulation and serotonergic effects
• Low sedation profile: Unlike benzodiazepines, standard doses in animal models do not produce motor impairment or sedation

What About Dependence and Tolerance?

Published animal studies and the Russian clinical experience suggest Selank does not produce the physical dependence or tolerance patterns seen with benzodiazepines. Long-term use in clinical trials did not show rebound anxiety or withdrawal symptoms upon discontinuation. However, the long-term human pharmacology of Selank is not as thoroughly characterized as conventional anxiolytics, and independent replication outside of Russian research groups remains limited.

How Is Selank Administered in Research?

Intranasal administration is the most common route — it bypasses first-pass hepatic metabolism and provides direct access to the CNS via the nasal mucosa. Subcutaneous injection is also used in research models. Oral administration is ineffective due to peptide degradation in the GI tract.

View Selank →

What Are the Limitations of Current Selank Research?

Several important limitations should be acknowledged:

• The majority of published research originates from Russian institutions, raising questions about independent replication
• Most mechanistic data is from animal models — the translation to human pharmacology is not fully characterized
• Long-term safety data in humans is limited
• Head-to-head comparisons with other anxiolytics (beyond diazepam in animal models) are largely absent
• The immunomodulatory effects in clinical populations need further characterization — their significance is not fully understood

Is Selank a Nootropic?

The term “nootropic” describes compounds that enhance cognitive function — particularly memory, learning, and executive function — without significant side effects. Selank meets several criteria used in nootropic research: it shows cognitive-enhancing effects in animal models without motor impairment or sedation, and it upregulates BDNF, which plays a key role in learning and memory consolidation.

In Russian clinical settings, Selank has been used for asthenic conditions — characterized by mental fatigue, poor concentration, and cognitive sluggishness — where it appears to improve subjective alertness and cognitive performance alongside anxiety reduction.

How Does Selank Compare to Other Anxiolytic Peptides?

Selank occupies a niche among peptide-based anxiolytics. Semax — a related Russian neuropeptide — has overlapping effects on BDNF and serotonin but is primarily characterized as a cognitive enhancer rather than anxiolytic. DSIP (Delta Sleep-Inducing Peptide) is another neuropeptide with anxiety-relevant activity but through very different mechanisms (sleep regulation, stress response normalization).

Among conventional anxiolytics, Selank’s profile most closely resembles that of buspirone (a non-benzodiazepine anxiolytic that acts on serotonin receptors) in terms of the absence of sedation and dependence risk — though the mechanisms differ substantially.

References

Disclaimer: This content is for research and educational purposes only. Not medical advice. All peptides are for laboratory use only and not intended for human consumption.